Vertex Acquires ViaCyte for $320 million to Accelerate a Functional CURE for Type 1 Diabetes

On July 11, 2022, Vertex announced that it would acquire private biotech ViaCyte for $320 million in cash, a move the company says is aimed at boosting the development of its stem cell therapy, VX-880. In addition to nabbing ViaCyte’s drug candidates, Vertex will acquire the biotech’s human stem cell lines, manufacturing facilities, and other relevant intellectual property. The deal, expected to close later this year, brings together two companies working toward such treatments under one roof, as ViaCyte is also working on its own stem cell therapy to try to provide a functional cure for type 1 diabetes. Each team had been at similar stages in the R&D process, with both touting proof-of-concept data and reaching early clinical trials within the last 13 months.

Join Robinhood with my link and we'll both get a free stock 🤝
https://join.robinhood.com/zhijiec

My Favorite Books on Biotech and Investing
The Code Breaker: Jennifer Doudna, Gene Editing, and the Future of the Human Race
https://amzn.to/3rgGAve

#diabetes
#ViaCyte
#VRTX
#VX880
#VCTX210
#vertex
#CRSP
#Semma
#DouglasMelton
#StemCell
#CellTherapy
#CathieWood
#ARKG
#Stock
#BiotechInvestor

0:00 Vertex Acquires Viacytes for $320M
3:01 Viacyte's Approach to T1D
8:04 Viacyte's Breakthrough Research
9:20 Viacyte's Product Pipeline
12:15 VX-880 vs. VCTX210
13:38 Subscribe for Future T1D Updates

***Disclaimer
I (Biotech Investor) hold a Ph.D. degree in life science and conducted 5 years of postdoctoral training in molecular biophysics at UC Berkeley. I am currently a full-time employee of a clinical-stage biopharmaceutical company, conducting early-stage drug discovery research. I have no professional affiliation with any of the companies or stocks discussed on this channel. This video is strictly for educational and entertainment purposes, and none of the contents in the video are for medical or financial/investment advice. I have no obligation to update, change or correct any information described in this video as news and stock prices change. The thoughts described in this channel are my own and do not reflect the company that I work for. This is not a solicitation to invest in any company I discussed in this channel, and I am not a financial or medical advisor. Investment involves risks and past performance should not be used as a gauge for future success. Seek a financial advisor to determine the appropriate investment strategies for your given circumstances. Investors should obtain their own independent financial advice and understand the risks associated with investment products/ services before making investment decisions.